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Abstract. The transcription factor growth arrest and DNA 
damage-inducible gene 153 (GADD153), also known as 
CHOP, is considered to function as a proapoptotic molecule. 
Overexpression of GADD153 leads to cell cycle arrest and/
or apoptosis. However, its clinical implications in non-small 
cell lung cancer (NSCLC) remain controversial. Therefore, we 
investigated the expression of GADD153 in stage I NSCLC 
using immunohistochemistry. Paraffin-embedded tissue 
sections from 76 patients, who were diagnosed with primary 
stage I NSCLC and had undergone a curative lung resection, 
were stained using an anti-GADD153 antibody. The intensity 
of GADD153 immunostaining was evaluated within the cell 
membrane and cytoplasm of invasive cancer components. The 
correlation between the intratumoral expression of GADD153 
and various clinical parameters were explored. GADD153 
was detected in 29 (38.2%) cases. No statistically significant 
difference in expression was demonstrated between stage IA 
and stage IB tumors (35.0 vs. 39.3%; P=0.735). The expres-
sion of GADD153 was not affected by histological subtypes 
or histological grades of differentiation. The intratumoral 
expression of GADD153 did not influence the overall survival 
rate (53.29 vs. 52.18 months; P=0.743) or disease-free survival 
rate (46.97 vs. 54.19 months; P=0.084) of stage I NSCLC 
patients. However, patients with GADD153 expression demon-
strated an improved disease-specific survival rate (28.80 
vs. 53.85 months; P=0.020). No patients with GADD153 
expression demonstrated distant metastasis (P=0.029). These 
data suggest that GADD153 expression may be a valuable 
prognostic factor of early-stage NSCLC in patients who have 
undergone curative lung resection.
Introduction
Non-small cell lung cancer (NSCLC) accounts for approxi-
mately 75-80% of all lung cancers and is the leading cause 
of cancer-related mortality worldwide (1,2). Twenty percent of 
stage I and 30% of stage II NSCLC patients (3) who are treated 
with curative intent experience recurrence of cancer, which 
is often incurable at the time of discovery, and have a 5-year 
survival rate of less than 50% (1). Despite years of intense 
efforts to control lung cancer mortality with surgical resection, 
chemotherapy and radiotherapy, NSCLC remains the leading 
cause of cancer-related mortality. This clearly indicates an 
urgent requirement for elucidating the mechanisms of lung 
cancer carcinogenesis, as well as discovering new approaches 
for its prevention and treatment.
The transcription factor growth arrest and DNA 
damage-inducible gene 153 (GADD153), also known as 
CHOP (4,5), is considered to function as a proapoptotic 
molecule. GADD153 belongs to the CCAAT/enhancer binding 
protein (C/EBP) family of transcription factors. It forms 
heterodimers with other C/EBP family proteins and changes 
their transcriptional activity (5,6).
GADD153 is ubiquitously expressed at a low level in 
several cell types, and its expression is induced by a variety 
of stress factors (5,7), including genotoxic stress, endoplasmic 
reticulum (ER) stress and nutrient depletion. Stress induces 
GADD153 expression at transcriptional and post-transcrip-
tional levels (4,8-11). ER stress is induced by environmental 
conditions that are frequently encountered in cancer growth; 
therefore, the role of ER stress in carcinogenesis and tumor 
progression is being actively researched (12,13). Overexpression 
of GADD153 has been reported to lead to cell cycle arrest and/
or apoptosis (14,15). Disruption of the GADD153 gene has been 
identified to render cells more resistant to ER stress‑induced 
apoptosis, while exogenous GADD153 is capable of inducing 
growth arrest and/or apoptosis (14-16). GADD153 is one of the 
important factors in the death of cancer cells and in the anti-
carcinogenic process, where it downregulates cell growth and 
survival rate. Studies have suggested that GADD153 triggers 
the critical early events leading to the initiation of apoptosis, 
which are considered to be of significance in the prognosis 
of early NCSLC (17). In this study, we aimed to determine 
whether the expression of GADD153 is an indicator of good 
Clinical significance of GADD153 expression 
in stage I non-small cell lung cancer
CHANG YOUL LEE1,  MYUNG GOO LEE1,  KYUNG CHAN CHOI2,  HEE MO KANG3  and  YOON SOO CHANG4
Departments of 1Internal Medicine and 2Pathology, Chuncheon Sacred Heart Hospital, 
Hallym University Medical Center; 3Department of Information Statistics, Hallym University; 
4Department of Internal Medicine, Yonsei University College of Medicine, Seoul 135-720, Republic of Korea
Received February 20, 2012;  Accepted May 29, 2012
DOI: 10.3892/ol.2012.768
Correspondence to: Dr Yoon Soo Chang, Department of Internal 
Medicine, Yonsei University College of Medicine, 8th Floor Annex 
Building, Gangnam Severance Hospital, 211 Eonju-ro, Gangnam-gu, 
Seoul 135-720, Republic of Korea
E-mail: yschang@yuhs.ac
Key words: non-small cell lung cancer, growth arrest and DNA 
damage-inducible gene, immunohistochemistry, prognosis
LEE et al:  GADD153 IN NSCLC 409
prognosis in stage I NSCLC patients. Consequently, we 
evaluated GADD153 expression in 76 stage I NSCLC tissue 
samples and investigated the correlation between expression 
and clinical and pathological findings.
Materials and methods
Study population and samples. Tissue specimens were 
obtained from 76 patients who were diagnosed with stage I 
primary NSCLC and underwent curative surgical removal of a 
primary lesion at the Yonsei Medical Center (Seoul, Republic 
of Korea) between 1995 and 1998. Pathological evaluation was 
established for histological classification and staging in all 
patients. No patient underwent radiotherapy or chemotherapy 
prior to or after surgery until the disease recurred. Of the 
76 patients, 56 (73.7%) were male and 20 (26.3%) were female. 
The age of the patients ranged from 31 to 83 years, with a 
mean age of 61.8±9.97 years, which was similar to the age 
distribution in our institution's large database of patients with 
stage I NSCLC (data not shown). All the clinical and patho-
logical information and follow-up data were based on studies 
from our tumor registry service. The study was reviewed and 
approved by the institution's Surveillance Committee and 
their permission was obtained to use tissue blocks and other 
pertinent information from patient files.
Im m u n oh i s to ch e m ic a l  s t a i n i ng  f o r  GA DD153. 
Paraffin-embedded 4 µm-thick tissue sections from 
76 primary stage I NSCLC samples were stained with mouse 
monoclonal antibody against human GADD153 (Abcam, Ltd., 
Cambridge, UK). All sections were deparaffinized in a series 
of xylene baths and rehydrated using a graded alcohol series. 
Paraffin sections were retrieved via microwave treatment and 
treated with 0.3% hydrogen peroxidase to block endogenous 
peroxidase activity. The sections were then incubated with the 
primary anti-GADD153 antibody.
Following incubation, the sections were processed 
using standard avidin-biotin immunohistochemical tech-
niques according to the manufacturer's instructions (Vector 
Laboratories, Burlingame, CA, USA). Diaminobenzidine was 
used as a chromogen and hematoxylin was used for counter-
staining. Adjacent normal-appearing bronchial epithelium 
within each tissue section served as an internal reference. The 
intensity of GADD153 immunostaining was evaluated within 
the cell membrane and cytoplasm of invasive cancer compo-
nents. Cell staining was regarded as positive or negative and 
all slides were independently evaluated by two pathologists 
who were unaware of the clinical and pathological information 
of the subjects. Cancer cells in at least 4 fields were counted 
at x200 magnification. The GADD153 immunoreactivity level 
was classified by the proportion of positive cells: 0, <5% posi-
tive cells; 1+, 5-30% positive cells; 2+, 30-50% positive cells; 3+, 
>50% positive cells. The intensity of GADD153 expression 
was also scored; 0, negative to weak; 1, moderate; 2, strong. 
The score was the sum of the intensity and the percentage of 
positive cells. A score of ≤1 was applied as a cut‑off point for 
loss of GADD153 expression.
Statistical analysis. Survival data of all patients were obtained 
from the Korea National Statistical Office. A two-sample 
t-test for independent samples and an χ2-test were used 
for continuous and categorical variables, respectively. The 
Kaplan-Meier estimator was used to compute survival rate 
probability as a function of time and the log-rank test was used 
to compare survival time between the groups. All statistical 
tests were two-sided. SPSS software (version 15.0) was used 
throughout and P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
NSCLC patient characteristics. The NSCLC cases included 
56 (73.7%) male and 20 (26.3%) female patients (age range, 
31-83 years; mean age, 61.8±9.97 years). The demographic 
characteristics of the patients are shown in Table I.
GADD153 immunohistochemistry. Immunohistochemical 
staining of GADD153 in normal and cancer tissue sections 
was conducted (Fig. 1). Immunoreactivity for the GADD153 
antibody was identified primarily in the cytoplasm of cancer 
cells. However, in the normal lung tissue, bronchial epithelial 
cells demonstrated weak immunoreactivity. The intensity of 
GADD153 staining in the cytoplasm was strong, granular and 
distinct in the lung cancer tissue. The number of cases with 
GADD153 positive staining was 29 (38.7%). There was hetero-
geneity of staining inside the same tumor with sporadic, patchy, 
focal or diffused patterns. Such intramural heterogeneity made 
scoring difficult in certain cases, but immunohistochemical 
staining of GADD153 was stable and reproducible. 
Correlation between GADD153 expression and various 
clinicopathological parameters. A total of 37 (48.7%) of the 
76 stage I NSCLCs were adenocarcinomas, 36 (47.3%) were 
squamous cell carcinomas and 3 (3.9%) were other histolog-
ical types of NSCLC. GADD153 expression was positive in 
29 (38.2%) and negative in 47 (61.8%) cases. We were able to 
classify 64 tissue samples for histological grade of differentia-
tion; 12 (54.5%) out of 22 were well-differentiated, 7 (29.2%) 
out of 24 were moderately differentiated and 6 (33.3%) out 
of 18 were poorly differentiated. Analysis of GADD153 
expression revealed that expression was not influenced by 
histological type (P=0.674) or differential grade (P=0.305). 
In a subgroup analysis among subtypes of adenocarcinoma, 
no differences were observed between bronchioloalveolar 
carcinomas and other subtypes of adenocarcinoma. The 
smoking status of the patients did not influence the expression 
of GADD153, and none of the patients with GADD153 expres-
sion experienced distant metastasis of statistical significance 
(P=0.029) (Table I).
Survival analysis. The total follow-up period of the patients 
who were alive at the time of analysis was 5 years. A total 
of 21 (27.6%) of the 76 patients died during the follow-up 
period; 11 (14.5%) succumbed to cancer-related events. The 
5-year survival rate probability of the patient population was 
72.3%, which is similar to previous results from a large-scale 
study (18). Overall survival and disease-free survival rate 
curves did not demonstrate statistically significant differ-
ences between NSCLC patients with and without GADD153 
expression (Fig. 2). However, the patients with GADD153 
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expression had a significantly improved disease-specific 
survival rate compared to patients with negative GADD153 
expression (28.80 vs. 53.85 months; P=0.020) (Table I; 
Fig 2). Subgroup analyses classified according to pathological 
diagnosis, grade of differentiation or TNM stages demon-
strated that GADD153 expression status did not influence 
disease-free, disease-specific and overall survival rate in 
NSCLC patients (data not shown).
Table I. Stage I NSCLC patient characteristics relative to GADD153 expression.
 GADD153 expression in tumor tissues
 -------------------------------------------------------------------------------------------------------------
 Positive Negative
Patient characteristics (n=29) (n=47) P-value
Gender
  Male 18 38 0.07 
  Female 11   9
Smoking status
  Smoker; packs/year, mean ± SD 21; 45.0±28.73 33; 35.2±19.69 0.112; 0.311
  Non-smoker   6   4
  Unknown   2 10
Pathology   0.674
  Adenocarcinoma 16 21 
  Squamous cell carcinoma 12 24
  Other   1   2
Histological grade   0.305
  Well-differentiated 12 10 
  Moderately differentiated   7 17
  Poorly differentiated   6 12
  Unclassified   4   8 0.735
TNM stage
  T1N0M0   7 13 
  T2N0M0 22 34
Distant metastasis   0   8 0.029
Mean survival time 
(months, 95% CI)
  Disease-free 54.19 (50.736-57.652) 46.97 (38.062-55.881) 0.084
  Disease‑specific 53.85 (50.702‑57.002) 28.80 (13.895‑43.705) 0.020
  Overall 52.18 (46.735-57.624) 53.29 (49.123-57.447) 0.743
GADD153, growth arrest and DNA damage‑inducible gene 153; NSCLC, non‑small cell lung cancer; CI, confidence interval. 
Figure 1. GADD153 expression in NSCLC tissue. (A) Adenocarcinoma and (B) squamous cell carcinoma of the lung demonstrate strong immunoreactivity 
with GADD153. (C) Bronchioloalveolar carcinoma demonstrates positive GADD153 expression (magnification, x200). GADD153, growth arrest and DNA 
damage-inducible gene 153; NSCLC, non-small cell lung cancer.
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Discussion
It has been well-established that mutational activation of the 
Ras gene is a key factor in human cancer development (19). 
Oncogenic Ras proteins transform cells via multiple down-
stream signaling cascades, which lead to the phosphorylation 
and activation of proliferation-inducing transcription factors, 
including Elk-1, Ets-2 and c-Myc (19,20). Oncogenic Ras 
has also been identified to downregulate the expression of 
proapoptotic proteins, including the Bcl-2 family protein Bak 
and the transcriptional repressor Par-4 (21-24). One study also 
demonstrated that oncogenic Ras downregulated GADD153 
expression at protein and mRNA levels (25).
GADD153, which belongs to the C/EBP family of tran-
scription factors, forms heterodimers with other members 
of the C/EBP family, resulting in the inhibition of tran-
scriptional activities (5,17). The GADD153 gene is typically 
induced in response to cellular stress (17). Previously, it has 
been reported that GADD153 expression may be regulated 
through various MAP kinase signaling pathways, and that 
the particular signaling pathway involved is dependent upon 
the type of stimuli (16,26,27). There is considerable evidence 
indicating that GADD153 is directly involved in the apoptosis 
pathway. It has been demonstrated that GADD153 upregulates 
the proapoptotic factor BH-3 (BIM) and downregulates the 
antiapoptotic Bcl-2 (28,29). Therefore, GADD153 increases 
cellular sensitivity to apoptosis by suppressing the transcription 
of antiapoptotic Bcl-2 (29). Previous studies have demonstrated 
that oncogenic Ras downregulates GADD153 expression and 
exogenous GADD153 inhibits Ras-induced cellular transforma-
tion (25). Therefore, GADD153 is important not only in killing 
cancer cells, but also in the anticarcinogenic process, where it 
downregulates cell growth and survival rate. A previous study 
has suggested that GADD153 may act as a critical marker of 
early response to cell injury, and each molecule is known to 
function in a different signal transduction pathway responsive 
to cell injury (30). The main role of the GADD153 gene is 
to block proliferation at G1 and 2 checkpoints in response to 
DNA damage. Transfection of the GADD153 gene into various 
cancer cell lines induces apoptosis without any stress-inducing 
factors, indicating that GADD153 is directly involved in the 
regulation of apoptosis (16). Furthermore, the GADD153 
protein plays a significant role in the induction of apoptosis 
of cancer cells treated with N-(4-hydroxyphenyl)retinamide, 
a synthetic retinoid, in a retinoic acid receptor-independent 
pathway (31,32). These results strongly suggest that the expres-
sion of the GADD153 gene is a new molecular mechanism of 
antitumor activity. However, studies on the clinical relevance 
of GADD153 expression in human cancer are extremely 
limited. In previous studies, increased expression of GADD153 
correlated with a lower tumor stage in colon cancer and with 
a higher survival rate in melanoma (33,34). A further study on 
lung cancer demonstrated that GADD153 expression correlated 
with a larger tumor size, higher pathological T stage, higher 
TNM stage and shorter overall survival rate (35). Therefore, 
we focused on the expression of GADD153 in patients with 
stage I (3) primary NSCLC and its association with clinical 
outcome. The aim of this study was to examine the expression 
of GADD153 in stage I NSCLC with respect to prognosis.
We examined the prognostic significance of GADD153 
expression in formalin‑fixed paraffin‑embedded tissues and 
revealed that GADD153 expression was downregulated in a 
significant amount of patients with stage I NSCLC. Overall, 29 
of 76 tumors (38.7%) expressed GADD153, and its expression 
was localized in the membrane and cytoplasm rather than in 
the nucleus of NSCLC cells. Notably, patients with GADD153 
expression demonstrated a positive correlation with improved 
disease‑specific survival rate (P=0.020). However, our data 
indicated that GADD153 expression was not associated 
with an improved overall survival rate and was only slightly 
associated with greater disease-free survival; no statistically 
significant differences were identified. We demonstrated that 
GADD153 expression was closely associated with and may 
have a role in the prevention of stage I NSCLC distant metas-
Figure 2. Survival analysis of stage I NSCLC patients according to GADD153 expression. Patients whose tumors expressed GADD153 had a significantly 
improved disease‑specific survival compared to those without GADD153 expression (P=0.02). GADD153, growth arrest and DNA damage‑inducible gene 153; 
NSCLC, non-small cell lung cancer.
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tasis (P=0.029); thus, the greater disease-specific survival 
rate in patients with GADD153 expression. Subsequently, we 
analyzed the association of GADD153 expression with the 
clinicopathological parameters of stage I NSCLC patients. 
GADD153 was associated with distant metastasis, but none 
of the other clinicopathological features of stage I NSCLC 
patients, suggesting that GADD153 may be involved in apop-
totic events preventing metastasis.
Since this study was a preliminary investigation, the 
number of patients with stage I NSCLC was relatively small 
(76 patients) and the longest follow-up time was 60 months. 
This study has revealed that GADD153 expression is a 
candidate marker that may aid in the stratification of patients 
according to prognosis following curative surgical removal 
of a primary lesion. Further comprehensive studies involving 
the mechanisms that induce expression of GADD153 in 
NSCLC are required to define the role of GADD153 in lung 
carcinogenesis. The significant association with survival rate 
observed in the present study is of particular relevance and 
should be confirmed in additional cohorts of patients.
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